In the Q2, Eli Lilly And Company's corporate clients experienced a decline by -13.04 % in their costs of revenue, compared to a year ago, sequentially costs of revenue grew by 7.39 %. During the corresponding time, Eli Lilly And Company recorded a revenue increase by 47.67 % year on year, sequentially revenue grew by 16.04 %. While revenue at the Eli Lilly And Company's corporate clients fell by -5.38 % year on year, sequentially revenue grew by 3.26 %.
Customers of Eli Lilly And Company saw their costs of revenue decline by -13.04 % in Q2 compare to a year ago, sequentially costs of revenue grew by 7.39 %, for the same period Eli Lilly And Company recorded revenue increase by 47.67 % year on year, sequentially revenue grew by 16.04 %.
Eli Lilly's Comment on Sales, Marketing and Customers
The company provides products and services to healthcare providers, wholesalers, pharmacy benefit managers, insurers, plan sponsors, employers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. In the United States, its products are primarily distributed through wholesalers serving pharmacies, physicians, healthcare professionals, and hospitals. The three wholesale distributors McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc. each represented a significant portion of the company's consolidated revenue in 2023, 2024, and 2025. Additionally, the company utilizes LillyDirect, a direct-to-patient digital healthcare platform, to deliver select medicines and provide patient support tools. Sales through LillyDirect increased in 2025, with ongoing efforts to expand access through new partnerships and tools.
Eli Lilly’s Comment on Sales, Marketing and Customers
The company provides products and services to healthcare providers, wholesalers, pharmacy benefit managers, insurers, plan sponsors, employers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. In the United States, its products are primarily distributed through wholesalers serving pharmacies, physicians, healthcare professionals, and hospitals. The three wholesale distributors McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc. each represented a significant portion of the company's consolidated revenue in 2023, 2024, and 2025. Additionally, the company utilizes LillyDirect, a direct-to-patient digital healthcare platform, to deliver select medicines and provide patient support tools. Sales through LillyDirect increased in 2025, with ongoing efforts to expand access through new partnerships and tools.
Sources:
Eli Lilly And Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Eli Lilly And Company’s corporate clients.
For your research, we’ve provided 9 tables on Eli Lilly And Company corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
93.2 %
3.4 % 